The prevention of invasive breast carcinoma

Cancer

Volumn 101, Issue 10, 2004, Pages 2147-2151

  Cady, Blake ^a,b   Chung, Maureen A ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST BIOPSY; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER SURGERY; CARCINOMA IN SITU; GENETIC DISORDER; HUMAN; INVASIVE CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NOTE; OVARIECTOMY; PATIENT ATTITUDE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; HUMANS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 7644227834     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20620     Document Type: Note

References (48)

1. Cuzick J, Powles T, Veronesi V, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361:296-300.
2. Olopade OI, Artioli G. Efficacy of risk-reducing salpingooophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004;10S:S5-S9.
3. Cuzick J, Forbes J, Edwards R, et al.; IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet. 2002; 360:817-824.
4. Chlebowski RT. Reducing the risk of breast cancer. Primary Care. 2000;343:191-198.
5. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from Tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95:526-532.
6. Michels K, Ekbom A. Caloric restriction and incidence of breast cancer. JAMA. 2004;291:1226-1230.
7. Wood WC. Advising women at high risk of breast cancer. Oncology. 2004;18:28-42.
8. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77-84.
9. Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol. 2000;18:284-286.
10. Fisher B, Costantino JP, Wickerman DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
11. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350: 1430-1441.
12. Cady B. How to prevent invasive breast cancer: detect and excise duct carcinoma in situ. J Surg Oncol. 1998;69:60-62.
13. Chlebowski RT, Collyar DE, Somerfield R, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999;17:1939-1955.
14. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580-585.
15. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004;100:1800-1806.
16. Morrow M, Hou N, Tchou J, et al. Acceptance of tamoxifen (TAM) chemoprevention varies with the cause of breast cancer risk [abstract]. Proc Am Soc Clin Oncol. 2003;22:538.
17. Yen TWF, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004;100:942-949.
18. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251-2256.
19. Page DL, Dupont WD, Rogers LW, et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197-2000.
20. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997;22:151-156.
21. Morrow M. The certainties and the uncertainties of ductal carcinoma in situ. J Natl Cancer Inst. 2004;96(6):424-425.
22. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):76-82.
23. Page DL, Lagios MD, Jensen RA. In situ carcinomas of the breast: ductal carcinoma in situ, Paget's disease, lobular carcinoma in situ. In: Bland KI, Copeland EM, editors. The breast. 3rd edition. Philadelphia: W.B. Saunders Company, 2004:255-278.
24. Vogel VG. Epidemiology of breast cancer. In: Bland KI, Copeland EM, editors. The breast. 3rd edition. St. Louis: W.B. Saunders Company, 2004:341-354.
25. Page DL, Rogers LW, Schuyler PA, Dupont WD, Jensen RA. The natural history of ductal carcinoma in situ of the breast. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2002:17-21.
26. Silverstein MJ, Lagios MD. Ductal carcinoma in situ with microinvasion. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2002:523-529.
27. Rosen PP. Invasive duct carcinoma. Assessment of prognosis, morphologic prognostic markers, and tumor growth rate. In: Rosen's breast pathology. Philadelphia: Lippincott Williams & Wilkins, 2001:325.
28. Schnitt SJ, Millis RR, Hanby AM, Oberman HA. The breast. In: Mills SE, editor. Sternberg's diagnostic surgical pathology. Philadelphia: Lippincott Williams & Wilkins, 2002:323-398.
29. Page DL, Simpson JF. Benign, high-risk, and premalignant lesions of the breast. In: Bland KI, Copeland EM, editors. The breast. 3rd edition. St. Louis: W.B. Saunders Company, 2004:175-198.
30. Mai KT, Yazdi HM, Burns BF, et al. Pattern of distribution of intraductal and infiltrating ducal carcinoma: a three-dimensional study using serial coronal giant sections of the breast. Hum Pathol. 2000;31:464-474.
31. Singletary SE. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg. 2002;194(2):202-216.
32. nd edition. Philadelphia: Lippincott Williams & Wilkins, 2002:482-493.
33. Recht A. Salvage of local-regional failure. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2002:539-544.
34. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol. 2001; 115:709-718.
35. Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology. 1996;29:397-409.
36. Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer. 1997;80:1740-1745.
37. Rudnicka L, Stachura J. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast. Pol J Pathol. 2000; 51(3):137-143.
38. Solin LJ, Vicini FA, Barrett W, et al. An international collaborative study: a 15-year experience. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2002:359-366.
39. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127:1023-1028.
40. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
41. Chiaverini L, Fulton JP, Darcy DM. Rhode Island cancer statistics review 2002. Table 3.1:3-4. Providence, RI: Rhode Island Cancer Registry, Rhode Island Department of Health, and the Hospital Association of Rhode Island, 2002.
42. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443-448.
43. Byers T, Mouchawar J, Marks J, et al. The American Cancer Society challenge goals. Cancer. 1999;86:715-727.
44. Coburn NG, Chung MA, Fulton J, Cady B. Decreased breast cancer tumor size, stage, and mortality in Rhode Island: an example of a well-screened population. Cancer Control 2004;11:222-230.
45. Otto SJ, Fracheboud J, Looman C, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003;361:1411-1417.
46. Tabar L, Smith RA, Vitak B, et al. Mammographic screening - a key factor in the control of breast cancer. Cancer J. 2003; 9:15-27.
47. Ernst MF, Roukema JA, Coebergh JW, et al. Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Res Treat. 2002;76:19-25.
48. Duffy SW, Tabar L, Vitak B, et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer. 2003;39: 1755-1760.